nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC6A3—Gilles de la Tourette syndrome	0.924	1	CbGaD
Lisdexamfetamine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00995	0.298	CbGeAlD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.00334	0.0855	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00333	0.0852	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.00324	0.083	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD2—Gilles de la Tourette syndrome	0.00302	0.0773	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—midbrain—Gilles de la Tourette syndrome	0.00251	0.0752	CbGeAlD
Lisdexamfetamine—SLC18A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00231	0.0591	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	0.00231	0.0591	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00224	0.0573	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—nervous system—Gilles de la Tourette syndrome	0.00208	0.0625	CbGeAlD
Lisdexamfetamine—SLC18A2—nervous system—Gilles de la Tourette syndrome	0.00206	0.0619	CbGeAlD
Lisdexamfetamine—ADRA1B—central nervous system—Gilles de la Tourette syndrome	0.002	0.0601	CbGeAlD
Lisdexamfetamine—SLC18A2—central nervous system—Gilles de la Tourette syndrome	0.00199	0.0595	CbGeAlD
Lisdexamfetamine—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.0019	0.0569	CbGeAlD
Lisdexamfetamine—ADRA1B—brain—Gilles de la Tourette syndrome	0.00159	0.0477	CbGeAlD
Lisdexamfetamine—SLC18A2—brain—Gilles de la Tourette syndrome	0.00158	0.0473	CbGeAlD
Lisdexamfetamine—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00156	0.0468	CbGeAlD
Lisdexamfetamine—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00155	0.0398	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.0015	0.045	CbGeAlD
Lisdexamfetamine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00148	0.0378	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00142	0.0363	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.00126	0.0377	CbGeAlD
Lisdexamfetamine—Dextroamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.00126	0.317	CrCbGaD
Lisdexamfetamine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.00121	0.0363	CbGeAlD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00121	0.0309	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—brain—Gilles de la Tourette syndrome	0.00119	0.0358	CbGeAlD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00117	0.03	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00109	0.028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00102	0.026	CbGpPWpGaD
Lisdexamfetamine—Amphetamine—SLC6A3—Gilles de la Tourette syndrome	0.00101	0.256	CrCbGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000986	0.0252	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—brain—Gilles de la Tourette syndrome	0.000962	0.0289	CbGeAlD
Lisdexamfetamine—Methamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000937	0.237	CrCbGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000918	0.0235	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000904	0.0231	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000765	0.0196	CbGpPWpGaD
Lisdexamfetamine—Amphetamine—DRD2—Gilles de la Tourette syndrome	0.000752	0.19	CrCbGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000643	0.0165	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000608	0.0156	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000507	0.013	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000438	0.0112	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000411	0.0105	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000388	0.00993	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000276	0.00707	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000233	0.00597	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000226	0.00579	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000211	0.0054	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000209	0.00534	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0002	0.00511	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000194	0.00496	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000191	0.00489	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000181	0.00462	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000171	0.00437	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000152	0.00389	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000148	0.00378	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000148	0.00378	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00014	0.00359	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000138	0.00352	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000127	0.00324	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	9.63e-05	0.00247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	8.59e-05	0.0022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.34e-05	0.00214	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.8e-05	0.002	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.77e-05	0.00199	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.58e-05	0.00194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.06e-05	0.00181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.44e-05	0.00139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.94e-05	0.00127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.61e-05	0.00118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.48e-05	0.00115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.17e-05	0.00107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.92e-05	0.000747	CbGpPWpGaD
